- New investors Kurma Partners (Eurazeo Group) and the European Innovation Council Fund (EICF) join the A2 syndicate led by Dutch life sciences VC BioGeneration Ventures.
- Proceeds will accelerate clinical development of TGD001, TargED’s first-in-class targeted thrombolytic following compelling Phase 1 data presented at ASH 2025 and ESOC 2026.
Utrecht, the Netherlands, June 24, 2025 – TargED Biopharmaceuticals B.V., a clinical-stage biotechnology company developing next-generation targeted treatments for thrombotic diseases, today announced the second and final closing of its Series A2 round totaling €40.4 million. The second closing brought in new investors Kurma Partners (Eurazeo Group) and the European Innovation Council Fund (EICF) with additional participation from Inkef Capital and Curie Capital.
The investment will support accelerated clinical development of TargED’s lead program, TGD001, a first-in-class, targeted thrombolytic designed to treat a broad range of thrombotic events by degrading both von Willebrand factor (VWF) and fibrin. The financing enables expansion of two Phase 1/2 clinical studies across Europe and the U.S. with first data expected later this year. In December 2025, the company reported positive Phase 1 first-in-human results for TGD001, demonstrating a favorable safety profile with no spontaneous bleeding events and exhibiting potent thrombolytic activity. Data were first presented in an oral session at the American Society of Hematology (ASH) Annual Meeting in December 2025 and updates presented in May 2026 at the European Stroke Organization Conference (ESOC).
“We are delighted to be expanding our syndicate with prestigious investors who share our conviction for TGD001, and are grateful for the continued support from all our existing investors,” said Kristof Vercruysse, Chief Executive Officer of TargED Biopharmaceuticals. “The momentum behind TGD001 continues to build we are now well positioned to expand clinical development towards proof of concept in at least two indications. We believe TGD001 has the potential to fundamentally reshape the treatment of thrombosis, offering a novel approach to universally dissolving life-threatening clots across multiple indications.”
“We have seen TargED mature into a clinical stage biotech leading development in indications that sadly have seen little to no innovation in decades. Today, TargED stands at the forefront of innovation in targeted thrombolysis and we are thrilled to be joining as a new investor,” said Rémi Droller, Managing Partner at Kurma Partners. “We are looking forward to working with the team to transform the treatment of thrombotic diseases”.
“Following TargED’s acceptance into the prestigious EIC Accelerator Program in 2025, we are now delighted to be able to join the company as an investor. We share the team’s conviction and belief that TGD001 has the potential to transform patient outcomes across multiple thrombotic diseases.” said Alexis Minte, Senior Investment Officer at the European Investment Bank.
Investor Syndicate
TargED’s investor base includes Andera Partners, BioGeneration Ventures, Curie Capital, FIRST, Fund+, Hadean Ventures, Inkef Capital, Kurma Partners (Eurazeo Group), Sunstone Life Science Ventures, and Utrecht Health Seed Fund.